- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Heron Therapeutics (HRTX)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 43.07 mm | 43.07 mm | 43.07 mm | 43.07 mm | 43.07 mm | 43.07 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 1.36 mm | (no burn) | (no burn) | 2.52 mm |
| Cash used (since last report) | n/a | n/a | 6.13 mm | n/a | n/a | 11.30 mm |
| Cash remaining | n/a | n/a | 36.94 mm | n/a | n/a | 31.77 mm |
| Runway (months of cash) | n/a | n/a | 27.1 | n/a | n/a | 12.6 |
| 13F holders | Current |
|---|---|
| Total holders | 162 |
| Opened positions | 26 |
| Closed positions | 38 |
| Increased positions | 42 |
| Reduced positions | 49 |
| 13F shares | Current |
|---|---|
| Total value | 172.99 bn |
| Total shares | 127.48 mm |
| Total puts | 42.40 k |
| Total calls | 3.02 mm |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Rubric Capital Management | 26.71 mm | $40.87 bn |
| Adage Capital Management | 8.85 mm | $15.93 mm |
| BLK BlackRock | 8.59 mm | $13.14 bn |
| Adage Capital Partners GP, L.L.C. | 8.50 mm | $13.01 bn |
| Vanguard | 8.16 mm | $12.48 bn |
| Velan Capital Investment Management | 6.99 mm | $10.69 bn |
| Tejara Capital | 4.66 mm | $7.13 bn |
| Palisade Capital Management | 3.93 mm | $6.01 bn |
| Tang Capital Partners | 3.76 mm | $0.00 |
| D. E. Shaw & Co. | 3.72 mm | $5.70 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 26 | Ira Duarte | Common Stock | Option exercise | Acquire M | No | No | 0 | 11,695 | 0.00 | 195,356 |
| 31 Jan 26 | Ira Duarte | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 11,695 | 0.00 | 140,332 |
| 31 Jan 26 | William P Forbes | Common Stock | Option exercise | Acquire M | No | No | 0 | 11,695 | 0.00 | 181,773 |
| 31 Jan 26 | William P Forbes | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 11,695 | 0.00 | 140,332 |
| 31 Jan 26 | Collard Craig A | Common Stock | Option exercise | Acquire M | No | No | 0 | 34,789 | 0.00 | 571,710 |
| 31 Jan 26 | Collard Craig A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 34,789 | 0.00 | 417,464 |
| 30 Jan 26 | Adam Morgan | Common Stock | Grant | Acquire A | No | No | 0 | 53,960 | 0.00 | 123,737 |
| 30 Jan 26 | Collard Craig A | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 800,336 | 0.00 | 800,336 |
| 30 Jan 26 | Collard Craig A | RSU Common Stock | Grant | Acquire A | No | No | 0 | 800,337 | 0.00 | 800,337 |